Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation

Transplantation

Volumn 80, Issue SUPPL. 2, 2005, Pages

  Land, Walter ^a,c   Vincenti, Flavio ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Ba kent University   (Germany)

Author keywords

CNI sparing; Mycophenolate mofetil; Renal transplantation; Steroid sparing; Toxicity sparing

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACNE; ACUTE GRAFT REJECTION; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; GROWTH RETARDATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; META ANALYSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; CALCINEURIN; CHILD; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RISK ASSESSMENT; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 27644431716     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000186386.13597.cb     Document Type: Review

References (81)

1. Flechner SM. Minimizing calcineurin inhibitor drugs in renal transplantation. Transplant Proc 2003; 35(Suppl 3): 118S.
2. McDevitt LM. Immunosuppressive agents on the horizon. J Pharm Practice 2003; 16: 434.
3. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
4. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 2004; 23(Suppl 5): 202S.
5. Mueller XM. Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants. Ann Thorac Surg 2004; 77: 354.
6. Hocker B, John U, Plank C, et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation 2004; 78: 228.
7. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829.
8. Land W. Future challenges in immunosuppression. Transplant Proc 1998; 30: 1580.
9. Ojo AO, Meier-Kriesche H-U, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
10. Meier-Kriesche H-U, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341.
11. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725.
12. Afzali B, Shah S, Chowdhury P, et al. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005; 79: 304.
13. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252.
14. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244.
15. Dudley C, Pohanka E, Riad H, et al. on behalf of the Mycophenolate Mofetil Creeping Creatine Study Group. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The "Creeping Creatinine" Study. Transplantation 2005; 79: 466.
16. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
17. Flechner SM, Kurian SM, Solez K, et al. De nova kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
18. Grinyo JM, Gil-Vernet S, Cruzado JM, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003;16:820.
19. Keunecke C, Rothenpieler U, Zanker B, et al. Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc 2000; 32: 6S.
20. Land W. Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation. Transplant Proc 1999; 31: 27S.
21. Kreis H, Cisterne J-M, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
22. Kuypers DRJ, Evenepoel P, Maes B, et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234.
23. Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004; 77: 1228.
24. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584.
25. Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501.
26. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536.
27. Smak Gregoor PJ, van Gelder T, van Besouw NM, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143.
28. Stegall MD, Larson TS, Prieto M, et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplant Proc 2003; 35(Suppl 3): 125S.
29. Theodorakis J, Schneeberger H, Illner W-D, et al. Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors. Transplant Proc 2000; 32: 9S.
30. Arbogast H, Hückelheim H, Schneeberger H, et al. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial. Clin Transplant 2005; 19: 309.
31. Tran HT, Acharya MK, McKay DB, et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000; 11: 1903.
32. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
33. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567.
34. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379.
35. Land W, Schneeberger H, Weiss M, et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. Transplant Proc 2001; 33(Suppl 4): 29S.
36. Zanker B, Schneeberger H, Rothenpieler U, et al. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. Transplantation 1998; 66: 44.
37. Merville P, Bergé F, Deminièrè C, et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004; 4: 1769.
38. González Molina M, Serón D, García del Moral R, et al. for the Spanish Mycophenolate Mofetil and Chronic Graft Nephropathy Study Group. Treatment of chronic allograft nephropathy with mycophenolate mofetil after kidney transplantation: a Spanish multicenter study. Transplant Proc 2002; 34: 335.
39. González Molina M, Serón D, García del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77: 215.
40. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
41. Anjum S, Andany MA, McClean JC, et al. Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am J Transplant 2002; 2: 179.
42. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
43. Vincenti F, Muehlbacher F, Nashan B, et al. for the LEEA29Y Study Group. Co-stimulation blockade with LEEA29Y in a calcineurin inhibitor free maintenance regimen in renal transplant: 6-month efficacy and safety. [Abstract 1037]. Paper presented at American Transplant Congress; May14-19, 2004; Boston, MA.
44. Nashan B, Grinyo J, Vincenti F, et al. Co-stimulation blockade with LEA29Y in renal transplant: improved renal function and CV/metabolic profile at 6 months compared with cyclosporine. [Abstract 1035]. Paper presented at American Transplant Congress; May 14-19, 2004; Boston, MA.
45. Balbontin F, Kiberd B, Fraser A, et al. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period. Clin Transplant 2005; 19: 225.
46. Weir MR, Klassen DK, Shen SY, et al. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. Transplantation 1990; 49: 41.
47. Kosch M, Hausberg M, Suwelack B. Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation 2003; 76: 1516.
48. Suwelack BM, Gerhardt UW, Hohage H. Influence of calcineurin-inhibitor free immunosuppression on carotid intima media thickness in chronic allograft nephropathy. [Abstract 659]. Paper presented at American Transplantation Congress; May 30-June 4, 2003; Washington, DC.
49. Greenstein SM, Sun S, Calderon TM, et al. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg Res 2000; 91: 123.
50. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865.
51. Anil Kumar MS, Xiao S-G, Fyfe B, et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant 2005; 19: 61.
52. Beaunoyer M, Busque S, St-Louis G, et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. Transplant Proc 2002; 34: 1694.
53. Birkeland SA. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998; 66: 1207.
54. Birkeland SA. Steroid-free immunosuppression in renal transplantation. A long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 1089.
55. Boletis JN, Konstadinidou I, Chelioti H, et al. Successful withdrawal of steroid after renal transplantation. Transplant Proc 2001; 33: 1231.
56. Borrows R, Loucaidou M, Van Tromp J, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004; 4: 1845.
57. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426.
58. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845.
59. Kim SJ, Lee KW, Lee DS, et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. Transplant Proc 2004; 36: 2098.
60. Kode R, Fa K, Chowdhury S, et al. Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation. Clin Transplant 2003; 17: 369.
61. Lebranchu Y, Aubert P, Bayle F, et al. on behalf of the M 55002 French Study Group. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and CellCept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. Transplant Proc 2000; 32: 396.
62. Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001; 1: 278.
63. Puig I, Mari JM, on behalf of the Spanish Group of the CellCept Study. Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: results of the Spanish Group. Transplant Proc 1999; 31: 2256.
64. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation. Transplantation 2005; 79: 807.
65. Smak Gregoor PJ, de Sévaux RGL, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365.
66. Sola E, Alférez MJ, Cabello M, et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. Transplant Proc 2002; 34: 1689.
67. Squifflet J-P, Vanrenterghem Y, van Hooff JP, et al. and the European Tacrolimus/MMF Transplantation Study Group. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34: 1584.
68. Teraoka S, Sato S, Kai K, et al. Early steroid withdrawal protocol using basiliximab in kidney transplantation. Transplant Proc 2004; 36 (Suppl 2): 478S.
69. ter Meulen CG, van Riemsdijk I, Hené RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor α therapy: a prospective, randomized, multicenter study. Am J Transplant 2004; 4: 803.
70. Tojimbara T, Nakajima I, Sato S, et al. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression. Transplant Proc 2004; 36: 2087.
71. Vanrenterghem Y, Lebranchu Y, Hené R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352.
72. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306.
73. Wlodarczyk Z, Walaszewski J, Ferner F, et al. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus- basedregimens. Transpl Int 2005; 18: 157.
74. Montini G, Murer L, Ghio L, et al. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Transpl Int 2005; 18: 36.
75. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76: 1331.
76. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
77. Woodle ES. Corticosteroid elimination in renal transplantation: pro. Transplant Proc 2002; 34: 1693.
78. Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548.
79. Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4: 980.
80. Boardman RE, Alloway RR, Alexander JW, et al. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant 2005; 5: 356.
81. Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13.